Outlook Therapeutics, Inc.
OTLK
$1.16
$0.01961.72%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 9.66M | 12.52M | 11.20M | -- | 4.53M |
| Gross Profit | -9.66M | -12.52M | -11.20M | -- | -4.53M |
| SG&A Expenses | 11.95M | 10.35M | 8.36M | 5.43M | 5.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.61M | 22.88M | 19.56M | 18.94M | 10.32M |
| Operating Income | -21.61M | -22.88M | -19.56M | -18.94M | -10.32M |
| Income Before Tax | 17.38M | 5.69M | 44.41M | -114.29M | -11.18M |
| Income Tax Expenses | -- | 0.00 | -- | 2.80K | -- |
| Earnings from Continuing Operations | 17.38M | 5.69M | 44.41M | -114.29M | -11.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.38M | 5.69M | 44.41M | -114.29M | -11.18M |
| EBIT | -21.61M | -22.88M | -19.56M | -18.94M | -10.32M |
| EBITDA | -21.58M | -22.85M | -19.53M | -18.91M | -10.29M |
| EPS Basic | 0.72 | 0.24 | 1.91 | -8.01 | -0.86 |
| Normalized Basic EPS | 0.48 | 0.16 | 0.99 | -4.63 | -0.49 |
| EPS Diluted | 0.72 | 0.24 | -0.89 | -8.01 | -0.86 |
| Normalized Diluted EPS | 0.48 | 0.16 | 0.90 | -4.63 | -0.49 |
| Average Basic Shares Outstanding | 24.23M | 23.73M | 23.23M | 14.27M | 13.01M |
| Average Diluted Shares Outstanding | 24.23M | 23.73M | 25.48M | 14.27M | 13.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
